Metoprolol CR/XL in the treatment of chronic heart failure

Pharmacotherapy

Volumn 21, Issue 5, 2001, Pages 604-613

  Gattis, W A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISOPROLOL; CARVEDILOL; METOPROLOL;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG FORMULATION; DRUG TOLERABILITY; FIRST PASS EFFECT; HEART FAILURE; PHARMACODYNAMICS; REVIEW; SURVIVAL; SUSTAINED RELEASE PREPARATION; TREATMENT OUTCOME;

EID: 0035001919     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.6.604.34551     Document Type: Review

References (33)

1. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade
2. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy
3. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease
4. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
5. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
6. Effects of controlled-release metoprolol on total mortality, hospitatizations, and well-being in patients with heart failure: The metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF)
7. The role of third-generation beta-blocking agents in chronic heart failure
8. Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol: A comparison with conventional tablets
9. The effect on heart rate of immediate and slow-release metoprolol in patients with chronic heart failure
10. Controlled release metoprolol formulations: A review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischemic heart disease
11. Design of a new multiple-unit controlled-release formulation of metoprolol - Metoprolol CR
12. 1-blockade in healthy subjects: A study on conventional metoprolol and metoprolol CR/ZOK formulations
13. Metoprolol: An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders
14. Pharmacokinetic and biopharmaceutic aspects of once/day treatment with metoprolol CR/ZOK: A review article
15. Steady-state bioavailability and day-to-day variability of a multiple-unit (CR/ZOK) and a single-unit (OROS) delivery system of metoprolol after once-daily dosing
16. Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once/day with conventional tablets once/day and in divided doses
17. Drug delivery and administration
18. The polymorphic oxidation of β-adrenoceptor antagonists: Clinical pharmacokinetic considerations
19. Proceedings: Relationship between the pharmacokinetic and pharmacodynamic properties of the beta-receptor antagonists alprenolol and metoprolol
20. Defective metabolism of metoprolol in poor hydroxylators of debrisoquine
21. Pharmacokinetics and pharmacodynamics of controlled-release metoprolol: A comparison with atenolol
22. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
23. β-adrenergic receptor blockade in chronic heart failure
24. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
25. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
26. Consensus recommendations for the management of chronic heart failure
27. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on evaluation and management of heart failure)
28. Treatment with β-blockers - The value of an even plasma concentration over 24 h
29. β-adrenergic-blocking agents in bronchospastic diseases: A therapeutic dilemma
30. Drugs, heart failure and quality of life: What are we achieving? What should we be trying to achieve?
31. Clinical relevance of pharmacokinetic differences between beta blockers